1. A compound, or a pharmaceutically acceptable salt thereof, selected from the up consisting of the compounds set forth in the following table:
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
2. A pharmaceutical formulation comprising as an active ingredient a therapeutically effective amount of a compound according to claim 1 in association with one or more pharmaceutically acceptable diluents, excipients andor inert carriers.
3. The pharmaceutical formulation according to claim 2, for use in the prevention andor treatment of mGluR5 receptor-mediated disorders.
4. A compound according to claim 1 for use in therapy.
5. The compound according to claim 1, for use in prevention andor treatment of mGluR5 receptor-mediated disorders.
6. The compound according to claim 5, wherein the disorder is a neurological disorder.
7. The compound according to claim 5, wherein the disorder is a psychiatric disorder.
8. The compound according to claim 5, wherein the disorder is selected from chronic and acute pain disorders.
9. The compound according to claim 5, wherein the disorder is a gastrointestinal disorder.
10. The compound according to claim 5, wherein the disorder is selected from the group consisting of Alzheimer’s disease, senile dementia, AIDS-induced dementia, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s Chorea, migraine, epilepsy, schizophrenia, depression, anxiety, acute anxiety, obsessive compulsive disorder, opthalmological disorders, diabetic retinopathies, glaucoma, auditory neuropathic disorders, chemotherapy induced neuropathies, post-herpetic neuralgia and trigeminal neuralgia, tolerance, dependency, addiction and craving disorders, neurodevelopmental disorders, autism, mental retardation, schizophrenia, Down’s Syndrome, pain related to migraine, inflammatory pain, neuropathic pain disorders, arthritis and rheumatitiod diseases, low back pain, post-operative pain, pain associated with angina, renal and billiary colic, menstruation, migraine gout, stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, cardiovascular diseases, GERD, and epilepsy.
11. The use of a compound according to claim 1 in the manufacture of a medicament for the use in the prevention andor treatment of mGluR5 receptor-mediated disorders.
12. A method of prevention andor treatment of mGluR5 receptor-mediated disorders, comprising administering to a mammal in need of such prevention andor treatment a therapeutically effective amount of a compound according to claim 1.
13. The method according to claim 12, wherein the disorder is a neurological disorder.
14. The method according to claim 12, wherein the disorder is a psychiatric disorder.
15. The method according to claim 12, wherein the disorder is selected from chronic and acute pain disorders.
16. The method according to claim 12, wherein the disorder is a gastrointestinal disorder.
17. The method according to claim 12, wherein the disorder is selected from the group consisting of Alzheimer’s disease, senile dementia, AIDS-induced dementia, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s Chorea, migraine, epilepsy, schizophrenia, depression, anxiety, acute anxiety, obsessive compulsive disorder, opthalmological disorders, diabetic retinopathies, glaucoma, auditory neuropathic disorders, chemotherapy induced neuropathies, post-herpetic neuralgia and trigeminal neuralgia, tolerance, dependency, addiction and craving disorders, neurodevelopmental disorders, autism, mental retardation, schizophrenia, Down’s Syndrome, pain related to migraine, inflammatory pain, neuropathic pain disorders, arthritis and rheumatitiod diseases, low back pain, post-operative pain, pain associated with angina, renal and billiary colic, menstruation, migraine gout, stroke, head trauma, anoxic and ischemic injuries, hypoglycemia, cardiovascular diseases and epilepsy.
18. A method for inhibiting the activation of mGluR5 receptors, comprising treating a cell containing said receptor with an effective amount of a compound according to claim 1.
The claims below are in addition to those above.
All refrences to claims which appear below refer to the numbering after this setence.
What is claimed is:
1. An attachment air inlet configuration for a turbine blade comprising:
an attachment having a root portion with a center plane;
a plurality of inlets in said root portion of said attachment communicating with at least two flow passageways in said blade;
each of said inlets having a non-circular shape with a major axis; and
said major axis being substantially normal to said root portion center plane.
2. An attachment air inlet configuration according to claim 1, wherein said attachment has a firtree configuration with a minimum neck section and wherein said blade has a plurality of ribs extending along an axis substantially perpendicular to said root portion center plane to define a plurality of inlet channels communicating with said inlets.
3. An attachment air inlet configuration according to claim 2, wherein each of said inlet channels has an elliptical shape.
4. An attachment air inlet configuration according to claim 2, further comprising each of said ribs having a first thickness in a region above the minimum neck section and a variable thickness greater than said first thickness in a region below said minimum neck section.
5. An attachment air inlet configuration according to claim 4, wherein said plurality of ribs include a central rib which forms two flow passageways in said blade and each of said inlet channels communicates with one of said flow passageways.
6. An attachment air inlet configuration according to claim 4, wherein each of said ribs occupies a first area in the region above said minimum neck section and a second area larger than said first area in the region below said minimum neck section.
7. An attachment air inlet configuration according to claim 2, wherein each of said inlet channels has a first flow area at said minimum neck section and a variable flow area larger than said first flow area beneath said minimum neck section.
8. An attachment air inlet configuration according to claim 6, further comprising each of said inlet channels having a curved transition section extending between a respective one of said inlets and said minimum neck section.
9. An attachment air inlet configuration according to claim 1, wherein said blade is a single crystal turbine blade.
10. An attachment air inlet configuration according to claim 9, wherein said single crystal turbine blade has a random secondary crystal orientation.
11. An attachment air inlet configuration according to claim 2, wherein said attachment has a rounded lower surface.